Showing 2751-2760 of 4802 results for "".
Currents
https://practicaldermatology.com/topics/skin-cancer-photoprotection/currents/20991/Recent Developments
https://practicaldermatology.com/columns/recent-developments/PD0509_05-php/22827/Re-introducing Ortho Dermatologics, Tremfya Approved, Obagi Acquired
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-re-introducing-ortho-dermatologics-tremfya-approved-obagi-acquired/18458/Valeant Pharmaceuticals is changing the name of its dermatology division to Ortho Dermatologics. In an exclusive interview with DermWireTV, Executive Vice President and dermatology industry veteran William Bill Humphries discusses the change. The FDA has approved Janssen Biotech's Tremfya (guselkumaDermWireTV: Pfizer, AbbVie JAKs for AD; Spray-on-Skin; Lubriderm Scholarships
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-pfizer-abbvie-jaks-for-ad-spray-on-skin-lubriderm-scholarships/20043/For the treatment of refractory moderate-to-severe atopic dermatitis, FDA has approved Pfizer’s Cibinqo (abrocitinib) for adults and AbbVie’s Rinvoq (upadacitinib) for patients 12 and older. Researchers at the Houston Methodist Research Institute have paired their patented RNA technologies with AvitAllergan Commemorates 25th Anniversary of the First Two Approved Uses of BOTOX® (onabotulinumtoxinA)
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/allergan-commemorates-25th-anniversary-of-the-first-two-approved-uses-of-botox-onabotulinumtoxina-/19136/Allergan, Inc. (NYSE: AGN) today announced the launch of a video recognizing the physician pioneers and patient communities who contributed to the development of BOTOX® (onabotulinumtoxinA), one of the most recognized pharmaceutical brands in the United States. The video kicks off a year-long campaiDermWireTV: Meet Crown Aesthetics, Revance to Market Teoxane Fillers, Almirall Collaborates
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-meet-crown-aesthetics-revance-to-market-teoxane-fillers-almirall-collaborates/19719/On the heels of recent acquisitions, Crown Laboratories is reorganizing and rebranding as three divisions: Crown Aesthetics, Crown Beauty, and Crown Therapeutics. Revance gains immediate and exclusive rights to commercialize Teoxane’s RHA 2, RHA 3, and RHA 4 products, which include lidocaine. A fourWest Meets East and Osteopathic Manipulative Medicine: Combining Treatment Modalities for Atopic Dermatitis
https://practicaldermatology.com/topics/general-topics/west-meets-east-and-osteopathic-manipulative-medicine-combining-treatment-modalities-for-atopic-dermatitis/20894/A Review of Complications of Biologic Therapy for Psoriasis
https://practicaldermatology.com/topics/general-topics/1109_02-php/22053/Therapeutic success requires clinicians to understand emerging and established safety concerns.The Microbiome in Acne: Where are We Now?
https://practicaldermatology.com/topics/acne-rosacea/the-microbiome-in-acne-where-are-we-now/23731/As research reveals connections of the microbiome to skin disease, clinicians may discover new approaches to managing the disease.Emollient-Based Therapy for AD: A Potential Role for Rebalancing the Microbiome
https://practicaldermatology.com/issues/supplements/emollient-based-therapy-for-ad-a-potential-role-for-rebalancing-the-microbiome/23136/